Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of FULC is 18 and suggests 65% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell